FDA approves Takeda’s Dexilant SoluTab

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday approved Takeda Pharmaceuticals’ Dexilant SoluTab (dexlansoprazole) delayed release tablets. The tablets, indicated to treat heartburn that’s associated with non-erosive gastroesophageal reflux disease (GERD) and maintain healed erosive esophagitis, are meant to melt in a patient’s mouth. 

 

The drug will be available in 30-mg delayed release disintegrating tablets, as well as 30- and 60-mg delayed release capsules. The capsules are indicated for the same illness as the dissolving tabs, as well as healing all grades of erosive esophagitis for up to 8 weeks.